As­traZeneca show­cas­es 83% risk re­duc­tion for long-act­ing Covid-19 an­ti­body at 6-month analy­sis

Up­dat­ed re­sults from As­traZeneca’s pre­ven­tion tri­al for its long-act­ing Covid-19 an­ti­body com­bo Evusheld sug­gest that the drug is even more ef­fec­tive at the six-month mark …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER